Effects of highly active antiretroviral therapy on paediatric metabolite levels

HIV Medicine

Volumn 7, Issue 1, 2006, Pages 16-24

  Rhoads, Margaret P ^a   Smith, C J ^b   Tudor Williams, G ^a   Kyd, P ^c   Walters, S ^a   Sabin, C A ^b   Lyall, E G H ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Cholesterol; HAART; High density lipoprotein; Lactate; Paediatric

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HEART PROTECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFANT; LACTATE BLOOD LEVEL; LONG TERM CARE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLITE; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD;

EID: 33646003839     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00337.x     Document Type: Article

References (32)

1. Gibb DM, Duong T, Tookey PA et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. Br Med J 2003; 327: 1019-1025.
2. Starr SE, Fletcher CV, Spector SA et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N Eng J Med 1999; 341: 1874-1881.
3. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: The PENTA 5 trial. Lancet 2002; 359: 733-740.
4. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
5. Friis-Moller N, Weber R, Reiss P et al. for the DAD Study Group Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-1193.
6. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14: 1309-1316.
7. Huynh TK, Luttichau HR, Roge BT, Gerstoft J. Natural history of hyperlactataemia in human immunodeficiency virus-1-infected patients during highly active antiretroviral therapy. Scand J Infect Dis 2003; 35: 62-66.
8. Hocqueloux L, Albertic C, Feugeas J-P et al. Prevalence, risk factors and outcome of hyperlactaaemia in HIV-infected patients. HIV Med 2003; 4: 18-23.
9. Wohl DA, Pilcher CD, Evans S et al. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr 2004; 35: 274-278.
10. Melvin AJ, Lennon S, Mohan K, Purnell JQ. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Human Retroviruses 2001; 17: 1117-1123.
11. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002; 21: 405-410.
12. Desai N, Mathur M, Weedon J. Lactate levels in children with HIV/AIDS on highly active antiretroviral therapy. AIDS 2003; 17: 1565-1567.
13. Noguera A, Fortuny C, Sanchez E et al. Hyperlactatemia in human immunodeficiency virus-infected children receiving antiretroviral treatment. Pediatr Infect Dis J 2003; 22: 778-782.
14. Vink NM, von Rossum AMC, Hartwig NG, de Groot R. Lipid and glucose metabolism in HIV-1-infected children treated with protease inhibitors. Arch Dis 2002; 86: 65-69.
15. Bitnun A, Sochett E, Babyn P et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003; 17: 1319-1327.
16. Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002; 110: 56.
17. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004; 18: 1443-1451.
18. Cheseaux J-J, Jotterand V, Aebi C et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: Relevance for cardiovascular diseases. J Acquir Immune Defic Syndr 2002; 30: 288-293.
19. Farley J, Gona P, Crain M, Cervia J, Lindsey J, Oleske J. Prevalence of hypercholesterolemia and associated risk factors among perinatally HIV-infected children (4-19 years) in PACTG 219C. X. Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 773].
20. Jaquet D, Levine M, Ortega-Rodriguez E et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000; 14: 2123-2128.
21. Ramos J, Garcia L, Rojo P et al. High prevalence of metabolic abnormalities in HIV infected children treated with HAART. X Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2003 [Abstract 772].
22. McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: Results of the First Pediatric Switch Study. Pediatrics 2003; 111: E275-e281.
23. Wiegman A, Rodenburg J, de Jongh S et al. Family history and cardiovascular risk in familial hypercholesterolemia data in more than 1000 children. Circulation 2003; 107: 1473-1478.
24. Sharland M, Blanche S, Castelli G, Ramos J Gibb DM for the PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy. HIV Med 2004; 5 (Suppl. 2): 61-86.
25. National Cholesterol Education Program. Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 525-584.
26. Tietz N. Clinical Guide to Laboratory Tests, 3rd edn. Philadelphia, PA: WB Saunders, 1995.
27. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem 1973; 19: 1350-1356.
28. Halloran P, Roetering H, Pisani T et al. Reference standardization and analytical performance of a liquid homogeneous high-density lipoprotein cholesterol method compared with chemical precipitation method. Ach Pathol Lab Med 1999; 123: 317-326.
29. Jacobs NJ, Vandemark PJ. The purification and properties of the alpha-glycerophosphate-oxidizing enzyme of Streptococcus faecalis 10C1. Arch Biochem Biophysics 1960; 88: 250-255.
30. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: Clinical presentation, pathophysiology and therapeutic strategies. J Clin Endocrinol Metab 2003; 88: 1961-1976.
31. van der Valk M, Reiss P. Lipid profiles associated with antiretroviral drug choices. Curr Opin Infect Dis 2003; 16: 19-23.
32. Maggiolo F, Quinzan G, Gregis G, Ripamonti D, Ravasio L, Suter F. HAART regimens with lower metabolic effect: A randomized, controlled trial. XV International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract WePeB5865].